Skip to main content

Dacomitinib Side Effects

Medically reviewed by Last updated on Nov 6, 2023.

Applies to dacomitinib: oral tablet.

Serious side effects of Dacomitinib

Along with its needed effects, dacomitinib may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking dacomitinib:

More common

Less common

Other side effects of Dacomitinib

Some side effects of dacomitinib may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Less common

For Healthcare Professionals

Applies to dacomitinib: oral tablet.


Very common (10% or more): Anemia (44%), hypoalbuminemia (44%), lymphopenia (42%)[Ref]


Very common (10% or more): Pain in extremity (14%), musculoskeletal pain (12%)[Ref]


Very common (10% or more): Conjunctivitis (19%)

Common (1% to 10%): Keratitis[Ref]


Very common (10% or more): Hyperglycemia (36%), hypocalcemia (33%), decreased appetite (31%), decreased weight (26%), hyponatremia (26%), alkaline phosphatase increased (22%), hypomagnesemia (22%)

Common (1% to 10%): Dehydration[Ref]


Very common (10% or more): Insomnia (11%)[Ref]


Very common (10% or more): ALT increased (40%), AST increased (35%), hyperbilirubinemia (16%)[Ref]


Very common (10% or more): Cough (21%), nasal mucosal disorder (i.e., epistaxis, nasal inflammation, nasal mucosal ulcer, rhinitis) (19%), dyspnea (13%), upper respiratory tract infection (12%), chest pain (10%)[Ref]


Very common (10% or more): Asthenia (13%)

Common (1% to 10%): Fatigue[Ref]


The most common (greater than 20%) adverse reactions were diarrhea (87%), rash (69%), paronychia (64%), stomatitis (45%), decreased appetite (31%), dry skin (30%), decreased weight (26%), alopecia (23%), cough (21%), and pruritus (21%).[Ref]

Nervous system

Common (1% to 10%): Dysgeusia[Ref]


Very common (10% or more): Creatinine increased (24%)[Ref]


Very common (10% or more): Rash (i.e., dermatitis acneiform, rash, rash maculopapular)/exfoliative skin reactions (78%), paronychia (i.e., nail infection, nail toxicity, onychoclasis, onycholysis, onychomadesis) (64%), dry skin (i.e., xerosis) (30%), alopecia (30%), pruritus (21%), palmar-plantar erythrodysesthesia syndrome (15%), dermatitis (11%)[Ref]


Very common (10% or more): Diarrhea (87%), stomatitis (i.e., mucosal inflammation) (45%), nausea (19%) constipation (13%), mouth ulceration (12%)

Common (1% to 10%): Vomiting[Ref]

Frequently asked questions


1. (2018) "Product Information. Vizimpro (dacomitinib)." Pfizer U.S. Pharmaceuticals Group

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.